Status:
COMPLETED
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
Lead Sponsor:
University of Illinois at Chicago
Conditions:
Acute Myeloid Leukemia
Acute Leukemia
Eligibility:
All Genders
10-65 years
Phase:
NA
Brief Summary
New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the...
Detailed Description
Treatment-related mortality and recurrence of disease account for the majority of treatment failures in allogeneic transplantation for advanced hematologic malignancies. The most commonly utilized con...
Eligibility Criteria
Inclusion
- Patients with the following diseases:
- Acute myeloid or lymphocytic leukemia in first remission at standard or high-risk for recurrence.
- Acute leukemia in greater than or equal to second remission, or with early relapse, or partial remission.
- Chronic myelogenous leukemia in accelerated phase or blast-crisis.
- Chronic myelogenous leukemia in chronic phase
- Recurrent or refractory malignant lymphoma or Hodgkin's disease
- Multiple myeloma.
- Chronic lymphocytic leukemia, relapsed or with poor prognostic features.
- Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic features.
- Severe aplastic anemia after failure of immunosuppressive therapy.
- Age 10-65 years.
- Zubrod performance status less than or equal to 2.
- Adequate cardiac and pulmonary function. Patients with decreased LVEF \< 40% or DLCO \< 50% of predicted will be evaluated by cardiology or pulmonary prior to enrollment on this protocol.
- Patient or guardian able to sign informed consent.
Exclusion
- Life expectancy is severely limited by concomitant illness.
- Serum creatinine greater than 1.5 mg/dL or Creatinine Clearance less than 50 ml/min .
- Serum bilirubin greater than or equal to 2.0 mg/dl, SGPT greater than 3 x upper limit of normal
- Evidence of chronic active hepatitis or cirrhosis
- HIV-positive
- Patient is pregnant
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01499147
Start Date
February 1 2000
End Date
May 1 2013
Last Update
November 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illinois at Chicago Medical Center
Chicago, Illinois, United States, 60612